MacroGenics Beats Cancer Drug Securities Suit At 4th Circ.
The Fourth Circuit affirmed Thursday the dismissal of a proposed securities class action accusing MacroGenics of overstating the success of its new breast cancer drug, finding the company consistently warned investors...To view the full article, register now.
Already a subscriber? Click here to view full article